ArticleCancers2023

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis.

Ni Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.